Widespread skin necrosis secondary to gemcitabine therapy

Patrick M. Zito, Adrianna M. Gonzalez, Joshua D. Fox, Megan Cronin, Nicholas MacKrides, Robert S. Kirsner, Anna J. Nichols

Research output: Contribution to journalArticle

Abstract

Gemcitabine, a pyrimidine nucleoside analogue, is an oncologic agent used in the treatment of cutaneous T-cell lymphoma (CTCL). Common dermatologic reactions associated with gemcitabine include alopecia, mild skin rash, and mucositis but skin necrosis is exceptional. Herein we present an unusual case of widespread skin necrosis mimicking toxic epidermal necrolysis in a 45-year-old woman receiving gemcitabine therapy for stage IIIA cutaneous T-cell lymphoma. This is the first reported case of a TEN-like reaction subsequent to gemcitabine treatment.

Original languageEnglish (US)
Pages (from-to)582-585
Number of pages4
JournalJournal of Drugs in Dermatology
Volume17
Issue number5
StatePublished - May 2018

ASJC Scopus subject areas

  • Dermatology

Fingerprint Dive into the research topics of 'Widespread skin necrosis secondary to gemcitabine therapy'. Together they form a unique fingerprint.

  • Cite this

    Zito, P. M., Gonzalez, A. M., Fox, J. D., Cronin, M., MacKrides, N., Kirsner, R. S., & Nichols, A. J. (2018). Widespread skin necrosis secondary to gemcitabine therapy. Journal of Drugs in Dermatology, 17(5), 582-585.